Cullinan Therapeutics, Inc. (CGEM) earnings
CGEM earnings moved a median of -2.46% by the close. Quarterly and annual CGEM reports and results, each read against the price at its own news timestamp. Back to the CGEM overview →
20 measured CGEM earnings events.
Where these CGEM earnings landedvs 20 measured CGEM earnings reactions
| Middle 50% of CGEM earnings reactions | -6.01% to +0.61% |
|---|---|
| Median reaction (to close) | -2.46% |
| Measured reactions | 20 |
Point-in-time · zero look-ahead
Half of the 20 CGEM earnings events with a measured close landed between -6.01% and +0.61%; 30% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio | Press release | +0.26% | -7.32% | |
| Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results | Press release | -1.64% | +1.58% | |
| Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results | Press release | -1.91% | -1.27% | |
| Form 10-K Cullinan Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -2.67% | -5.27% | |
| Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results | Press release | -1.76% | -0.41% | |
| Form 10-Q Cullinan Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -1.76% | -0.41% | |
| Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results | Press release | +1.45% | -7.62% | |
| Form 10-Q Cullinan Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +1.45% | -7.62% | |
| Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results | Press release | +1.44% | +1.44% | |
| Form 10-Q Cullinan Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +1.44% | +1.44% | |
| Form 10-K Cullinan Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +1.50% | -0.35% | |
| Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results | Press release | +0.55% | -5.58% | |
| Form 10-Q Cullinan Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +0.55% | -5.58% | |
| Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results | Press release | -5.29% | -3.65% | |
| Form 10-Q Cullinan Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -5.29% | -3.65% | |
| Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results | Press release | -2.37% | -11.12% | |
| Form 10-Q Cullinan Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -2.37% | -11.12% | |
| Form 10-K Cullinan Oncology, Inc. For: Dec 31 | SEC filing · Form 10-K | +1.85% | +0.71% | |
| Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results | Press release | +0.00% | +0.61% | |
| Form 10-Q Cullinan Oncology, Inc. For: Sep 30 | SEC filing · Form 10-Q | +0.00% | +0.61% |
Keep exploring
More CGEM: analyst actions → · SEC filings → · CGEM overview →